首页> 外文期刊>Nutrition & Diabetes >Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal modelsOpen
【24h】

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal modelsOpen

机译:钠/葡萄糖共转运蛋白2抑制剂Tofogliflozin在糖尿病和肥胖动物模型中可减轻体重增加和脂肪积累

获取原文
           

摘要

Objective:Tofogliflozin, a highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2), induces urinary glucose excretion (UGE), improves hyperglycemia and reduces body weight in patients with Type 2 diabetes (T2D). The mechanisms of tofogliflozin on body weight reduction were investigated in detail with obese and diabetic animal models.
机译:目的:Tofogliflozin是一种高度选择性的钠/葡萄糖共转运蛋白2(SGLT2)抑制剂,可诱导2型糖尿病(T2D)患者的尿糖排泄(UGE),改善高血糖症并减轻体重。用肥胖和糖尿病动物模型详细研究了Tofogliflozin减轻体重的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号